Cellectis SA
(NAS:CLLS)
$
2.25
-0.15 (-6.25%)
Market Cap: 228.13 Mil
Enterprise Value: 46.61 Mil
PE Ratio: 0
PB Ratio: 1.42
GF Score: 54/100 
Cellectis SA at Goldman Sachs Global Healthcare Conference Transcript
Jun 16, 2022 / 05:00PM GMT
Release Date Price:
$2.39
(-4.40%)
Matthew (Trades, Portfolio)atorre
Goldman Sachs Group, Inc., Research Division - Research Analyst
Good morning, everyone, and thank you for joining us for Day 4 of the Goldman Sachs Healthcare Conference. We're really pleased to have Cellectis here. And with us, we have Bing Wang, CFO. So just to get started. So Cellectis is a clinical-stage biotech company using its platform to develop cell therapies.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers